United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting shares under a pre-arranged trading plan. On March 30, 2026, she exercised options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share, converting a derivative position into common stock.

That same day she sold 9,500 common shares in multiple open-market transactions at prices generally around $581–$603 per share, as part of a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she held 40,513 common shares directly, in addition to indirect holdings reported as held by her spouse and various family trusts.

Insights

Insider transactions analyst

CEO executes pre-planned option exercise-and-sell, with modest net share reduction.

Martine Rothblatt exercised stock options for 9,500 shares at an exercise price of $146.03, then sold the same 9,500 shares in multiple open-market trades around $581–$603 on March 30, 2026. This matches a classic exercise-and-sell pattern.

The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Such plans typically indicate routine diversification rather than opportunistic timing.

After the transactions, Rothblatt directly owned 40,513 common shares and also reported significant indirect holdings through her spouse and family trusts. Given her substantial remaining exposure and the pre-planned nature of the trades, this activity appears routine and not thesis-changing.

Insider Trade Summary 10b5-1

Net Seller: 9,500 shares ($5,610,564)

Net Sell 26 txns

Insider ROTHBLATT MARTINE A

Role Chairperson & CEO

Sold 9,500 shs ($5.61M)

Type	Security	Shares	Price	Value
Exercise	Stock Option	9,500	$0.00	--
Exercise	Common Stock	9,500	$146.03	$1.39M
Sale	Common Stock	80	$581.74	$47K
Sale	Common Stock	160	$583.40	$93K
Sale	Common Stock	86	$584.8038	$50K
Sale	Common Stock	354	$586.0702	$207K
Sale	Common Stock	1,346	$587.3432	$791K
Sale	Common Stock	1,790	$588.3308	$1.05M
Sale	Common Stock	1,734	$589.1799	$1.02M
Sale	Common Stock	1,068	$590.3198	$630K
Sale	Common Stock	602	$591.2445	$356K
Sale	Common Stock	120	$592.1933	$71K
Sale	Common Stock	240	$593.8266	$143K
Sale	Common Stock	400	$594.6064	$238K
Sale	Common Stock	320	$595.80	$191K
Sale	Common Stock	319	$596.8696	$190K
Sale	Common Stock	201	$598.5224	$120K
Sale	Common Stock	280	$599.4837	$168K
Sale	Common Stock	182	$600.5182	$109K
Sale	Common Stock	98	$601.5729	$59K
Sale	Common Stock	120	$602.7167	$72K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 40,500 shares (Direct); Common Stock — 50,013 shares (Direct); Common Stock — 166 shares (Indirect, by Spouse)

Footnotes (1)

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026. This transaction was executed in multiple trades at prices ranging from $591.98 to $592.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $593.16 to $594.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $594.19 to $595.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $595.40 to $596.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $596.50 to $597.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $597.81 to $598.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $599.04 to $599.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $600.14 to $600.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $601.16 to $602.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $602.16 to $603.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $583.29 to $583.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. This transaction was executed in multiple trades at prices ranging from $584.67 to $585.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $585.68 to $586.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $586.78 to $587.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $587.78 to $588.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $588.79 to $589.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $589.81 to $590.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $590.83 to $591.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 9,500 shares Exercise price: $146.03 per share Shares sold: 9,500 shares +5 more

8 metrics

Options exercised 9,500 shares Stock options exercised on March 30, 2026

Exercise price $146.03 per share Stock option exercise price for 9,500 shares

Shares sold 9,500 shares Open-market sales on March 30, 2026

Sale price range About $581–$603 per share Multiple trades with weighted-average prices disclosed in footnotes

Direct holdings after 40,513 shares Common stock directly owned after reported transactions

Largest indirect trust holding 324,518 shares Common stock held by a family trust with shared investment power

10b5-1 plan options pool 1,734,410 options Options subject to trading plan expiring March 17, 2027

10b5-1 plan end date December 31, 2026 Latest possible termination date of the trading plan

Key Terms

Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock options financial

"This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

weighted average price financial

"The price reported above reflects the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

family trusts financial

"Shares held in family trusts as to which the Reporting Person shares investment power..."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTHBLATT MARTINE A

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairperson & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/30/2026		M(1)		9,500	A	$146.03	50,013	D
Common Stock	03/30/2026		S(1)		80	D	$581.74	49,933	D
Common Stock	03/30/2026		S(1)		160	D	$583.4(2)	49,773	D
Common Stock	03/30/2026		S(1)		86	D	$584.8038(3)	49,687	D
Common Stock	03/30/2026		S(1)		354	D	$586.0702(4)	49,333	D
Common Stock	03/30/2026		S(1)		1,346	D	$587.3432(5)	47,987	D
Common Stock	03/30/2026		S(1)		1,790	D	$588.3308(6)	46,197	D
Common Stock	03/30/2026		S(1)		1,734	D	$589.1799(7)	44,463	D
Common Stock	03/30/2026		S(1)		1,068	D	$590.3198(8)	43,395	D
Common Stock	03/30/2026		S(1)		602	D	$591.2445(9)	42,793	D
Common Stock	03/30/2026		S(1)		120	D	$592.1933(10)	42,673	D
Common Stock	03/30/2026		S(1)		240	D	$593.8266(11)	42,433	D
Common Stock	03/30/2026		S(1)		400	D	$594.6064(12)	42,033	D
Common Stock	03/30/2026		S(1)		320	D	$595.8(13)	41,713	D
Common Stock	03/30/2026		S(1)		319	D	$596.8696(14)	41,394	D
Common Stock	03/30/2026		S(1)		201	D	$598.5224(15)	41,193	D
Common Stock	03/30/2026		S(1)		280	D	$599.4837(16)	40,913	D
Common Stock	03/30/2026		S(1)		182	D	$600.5182(17)	40,731	D
Common Stock	03/30/2026		S(1)		98	D	$601.5729(18)	40,633	D
Common Stock	03/30/2026		S(1)		120	D	$602.7167(19)	40,513	D
Common Stock								166	I	by Spouse
Common Stock								324,518	I	by Trust(20)
Common Stock								258,117	I	by Trust(21)
Common Stock								45,596	I	by Trust(22)
Common Stock								10,962	I	by Trust(23)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$146.03	03/30/2026		M(1)			9,500	03/15/2020	03/15/2027	Common Stock	9,500	$0.00	40,500	D

Explanation of Responses:

1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 17, 2027; or (b) December 31, 2026.

2. This transaction was executed in multiple trades at prices ranging from $583.29 to $583.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $584.67 to $585.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $585.68 to $586.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $586.78 to $587.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $587.78 to $588.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $588.79 to $589.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

8. This transaction was executed in multiple trades at prices ranging from $589.81 to $590.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

9. This transaction was executed in multiple trades at prices ranging from $590.83 to $591.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

10. This transaction was executed in multiple trades at prices ranging from $591.98 to $592.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

11. This transaction was executed in multiple trades at prices ranging from $593.16 to $594.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

12. This transaction was executed in multiple trades at prices ranging from $594.19 to $595.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

13. This transaction was executed in multiple trades at prices ranging from $595.40 to $596.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

14. This transaction was executed in multiple trades at prices ranging from $596.50 to $597.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

15. This transaction was executed in multiple trades at prices ranging from $597.81 to $598.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

16. This transaction was executed in multiple trades at prices ranging from $599.04 to $599.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

17. This transaction was executed in multiple trades at prices ranging from $600.14 to $600.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

18. This transaction was executed in multiple trades at prices ranging from $601.16 to $602.08. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

19. This transaction was executed in multiple trades at prices ranging from $602.16 to $603.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

20. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

21. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

22. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

23. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did UNITED THERAPEUTICS (UTHR) CEO Martine Rothblatt do in this Form 4?

The CEO exercised stock options for 9,500 shares at $146.03 per share, then sold 9,500 common shares in multiple open-market trades around $581–$603 on March 30, 2026, all under a pre-arranged Rule 10b5-1 trading plan.

How many UNITED THERAPEUTICS (UTHR) shares does Martine Rothblatt hold after these transactions?

After the reported transactions, Martine Rothblatt directly held 40,513 UNITED THERAPEUTICS common shares. The filing also lists additional indirect holdings through her spouse and several family trusts, each with disclosed share counts as of the reported date.

Were Martine Rothblatt’s UNITED THERAPEUTICS (UTHR) stock sales pre-planned?

Yes. A footnote explains that the option exercise and resulting share sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, with the plan running until specific option exercises are completed or December 31, 2026.

What is the scale of the UNITED THERAPEUTICS (UTHR) option exercise reported?

The filing shows an exercise of stock options for 9,500 shares of UNITED THERAPEUTICS common stock at an exercise price of $146.03 per share. This converted a derivative position into directly held common shares before those shares were sold the same day.

What Rule 10b5-1 plan details are disclosed for UNITED THERAPEUTICS (UTHR) CEO?

The Rule 10b5-1 plan was adopted on November 7, 2025. It will continue until the earlier of exercising 1,734,410 stock options, all expiring on March 17, 2027, or December 31, 2026, governing the option exercises and related share sales.

Does the UNITED THERAPEUTICS (UTHR) Form 4 show indirect holdings for Martine Rothblatt?

Yes. The Form 4 reports indirect common stock holdings attributed to her spouse and multiple family trusts. Each entry lists shares held, such as 324,518 shares in one trust, reflecting broader family and trust ownership beyond her directly held 40,513 shares.